Cytokinetics, Incorporated (CYTK)

Cytokinetics Statistics

Total Valuation

Cytokinetics has a market cap or net worth of $3.58 billion. The enterprise value is $3.58 billion.

Market Cap	3.58B
Enterprise Value	3.58B

Important Dates

The last earnings date was Tuesday, May 6, 2025, after market close.

Earnings Date	May 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Cytokinetics has 119.43 million shares outstanding. The number of shares has increased by 18.23% in one year.

Current Share Class	119.43M
Shares Outstanding	119.43M
Shares Change (YoY)	+18.23%
Shares Change (QoQ)	+0.36%
Owned by Insiders (%)	0.44%
Owned by Institutions (%)	111.77%
Float	118.86M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	184.96
Forward PS	53.22
PB Ratio	-13.51
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	186.40
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.99

Current Ratio	5.99
Quick Ratio	5.89
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-6.14

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-34.12%
Return on Invested Capital (ROIC)	-69.69%
Return on Capital Employed (ROCE)	-51.22%
Revenue Per Employee	$38,590
Profits Per Employee	-$1.24M
Employee Count	498
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -48.18% in the last 52 weeks. The beta is 0.81, so Cytokinetics's price volatility has been lower than the market average.

Beta (5Y)	0.81
52-Week Price Change	-48.18%
50-Day Moving Average	39.80
200-Day Moving Average	48.68
Relative Strength Index (RSI)	27.76
Average Volume (20 Days)	2,319,772

Short Selling Information

The latest short interest is 14.48 million, so 12.12% of the outstanding shares have been sold short.

Short Interest	14.48M
Short Previous Month	13.95M
Short % of Shares Out	12.12%
Short % of Float	12.18%
Short Ratio (days to cover)	6.43

Income Statement

In the last 12 months, Cytokinetics had revenue of $19.22 million and -$615.26 million in losses. Loss per share was -$5.30.

Revenue	19.22M
Gross Profit	-338.46M
Operating Income	-565.64M
Pretax Income	-545.28M
Net Income	-615.26M
EBITDA	-556.14M
EBIT	-565.64M
Loss Per Share	-$5.30

Balance Sheet

The company has $938.22 million in cash and $922.16 million in debt, giving a net cash position of $16.06 million or $0.13 per share.

Cash & Cash Equivalents	938.22M
Total Debt	922.16M
Net Cash	16.06M
Net Cash Per Share	$0.13
Equity (Book Value)	-266.41M
Book Value Per Share	-2.23
Working Capital	796.33M

Cash Flow

In the last 12 months, operating cash flow was -$398.00 million and capital expenditures -$9.57 million, giving a free cash flow of -$407.57 million.

Operating Cash Flow	-398.00M
Capital Expenditures	-9.57M
Free Cash Flow	-407.57M
FCF Per Share	-$3.41

Margins

Gross Margin	n/a
Operating Margin	-2,943.30%
Pretax Margin	-3,201.47%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Cytokinetics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.23%
Shareholder Yield	-18.23%
Earnings Yield	-17.10%
FCF Yield	-11.33%

Analyst Forecast

The average price target for Cytokinetics is $75.65, which is 152.17% higher than the current price. The consensus rating is "Buy".

Price Target	$75.65
Price Target Difference	152.17%
Analyst Consensus	Buy
Analyst Count	18
Revenue Growth Forecast (5Y)	145.04%
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on June 25, 2013. It was a reverse split with a ratio of 0.1666666:1.

Last Split Date	Jun 25, 2013
Split Type	Reverse
Split Ratio	0.1666666:1

Scores

Cytokinetics has an Altman Z-Score of -1.46 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.46
Piotroski F-Score	3